Lineage Cell Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Lineage Cell Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Lineage Cell Therapeutics: 5 sponsored US clinical trials, 1 recruiting.
Lineage Cell Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Spinal Cord Injuries, with 2 trials.
Upper-quartile sponsor footprint
Lineage Cell Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
NCT06841770
LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
NCT05975424
LTFU Study of Subjects Who Received GRNOPC1
NCT05919563
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
NCT02302157
Safety Study of GRNOPC1 in Spinal Cord Injury
NCT01217008
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
What is open in the Lineage Cell Therapeutics pipeline
1 recruiting of 5 indexed (20% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Spinal Cord Injuries (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lineage Cell Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Lineage Cell Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Lineage Cell Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of Lineage Cell Therapeutics or any single study.
- 1 of Lineage Cell Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Spinal Cord Injuries is the condition Lineage Cell Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Spinal Cord Injuries trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Lineage Cell Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.